Role of complement in antiphospholipid antibody-mediated thrombosis

Current Rheumatology Reports

Volumn 9, Issue 3, 2007, Pages 205-211

  O'Neil, Kathleen M ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C5A; FONDAPARINUX; HEPARIN; HIRUDIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; DRUG CONTRAINDICATION; DRUG EFFICACY; ENDOCARDITIS; FETUS WASTAGE; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; INTRAUTERINE GROWTH RETARDATION; LUNG INFARCTION; MOLECULAR CLONING; MORBIDITY; NEUTROPHIL; NONHUMAN; PATHOGENESIS; REVIEW; SPONTANEOUS ABORTION; STROKE; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; TISSUE INJURY;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 34250692976     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0033-y     Document Type: Review

References (50)

1. Hazeltine M, Rauch J, Danoff D, et al.: Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coomb's and hypocomplementemia. J Rheumatol 1988, 15:80-86.
2. Unander A, Norberg R, Hahn L, Arfors L: Anticardiolipin antibodies and complement in ninety-nine women with habitual abortion. Am J Obstet Gynecol 1985, 156:114-119.
3. Cheng H, Yap S: Anticardiolipin antibody and complement. Arthritis Rheum 1988, 31:1211-1212.
4. Petri M, Golbus M, Anderson R, et al.: Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with habitual abortion: a controlled, prospective study of forty-four women. Arthritis Rheum 1987, 30:601-606.
5. Davis W, Brey R: Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992, 10:455-460.
6. Ziporen L, Goldberg I, Arad M, et al.: Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996, 5:196-205.
7. Hammond A, Rudge A, Loizou S, et al.: Reduced number of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Arthritis Rheum 1989, 32:259-264.
8. Navratil J, Manzi S, Kao A, et al.: Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum 2006, 54:670-674.
9. Stewart M, Etches W, Gordon P: Antiphospholipid antibody-dependent C5b-9 formation. Br J Haematol 1997, 96:451-457.
10. Santiago M, Gaburo N Jr, de Oliveira R, Cossermelli W: Complement activation by anticardiolipin antibodies. Ann Rheum Dis 1991, 50:249-250.
11. Odorczuk M, Keil L, DeBari V: Binding of complement component C1q to anti-beta2 gylcoprotein I antibodies from patients with the antiphospholipid syndrome. Inflamm Res 1999, 48:524-526.
12. Munakata Y, Saito T, Matsuda K, et al.: Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb Haemost 2000, 83:728-731.
13. Shinzato M, Bueno C, Trindade-Viana V, et al.: Complement-fixing activity of anticardiolipin antibodies in patients with and without thrombosis. Lupus 2005, 14:953-958.
14. O'Neil K, Kershen L, Madduri D, Merrill JT: In vitro complement activation by anticardiolipin antibodies predicts coagulopathy [abstract 608]. Arthritis Rheum 2005, 52(Suppl):S251.
15. Wilson W, Scopelitis E, Micalski J, et al.: Familial anti-cardiolipin antibodies and C4 deficiency genotypes that coexist with MHC DQB1 risk factors. J Rheumatol 1995, 22:227-235.
16. Bentolila S, Fremeaux-Bacchi V, Weiss L, et al.: High frequency of C4 "null" alleles in primary antiphospholipid syndrome. Ann Med Interne (Paris) 1996, 147:115-116.
17. Julia M, Matamoros N, Mila J, et al.: Homozygous complement factor deficiency and primary antiphospholipid syndrome: a clinical and serological study. Ann Rheum Dis 1995, 54:530-531.
18. Colucci A, DiLorenzo G, Ingrassia A, et al.: Blood antiphospholipid antibody levels are influenced by age, sex and HLA-B9, DR3 phenotype. Exp Clin Immunogenet 1992, 9:72-79.
19. Branch D, Dudley D, Mitchell M, et al.: Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990, 163:210-216.
20. Blank M, Cohen J, Toder V, Shoenfeld Y: Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal antibodies. Proc Natl Acad Sci U S A 1991, 88:3069-3073.
21. Ikematsu W, Luan F, LaRosa L, et al.: Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis Rheum 1998, 41:1026-1039.
22. Piona A, LaRosa L, Tincani A, et al.: Placental thrombosis and fetal loss after passive transfer of mouse lupus mononclonal or human polyclonal anti-cardiolipin antibodies in pregnant BALB/c mice. Scand J Immunol 1995, 41:427-432.
23. Magid M, Kaplan C, Sammaritano L, et al.: Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 1998, 179:226-234.
24. Out H, Kooijman C, Bruinse H, Derksen R: Histopathological findings in placentae from patients with intrauterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991, 41:179-186.
25. Berman J, Girardi G, Salmon J: TNF-a is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:485-490. This paper identifies TNF as a major mediator of aPL-induced damage in the mouse model of APS pregnancy and shows that TNF inhibitor therapy ameliorates disease.
26. Papa N, Raschi E, Moroni G, et al.: Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and pro-inflammatory phenotype in vitro. Lupus 1995, 8:423-429.
27. Pierangeli S, Colden-Stanfield M, Liu X, et al.: Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 1999, 99:1997-2002.
28. Simantov R, LaSala J, Lo S, et al.: Activation of cultured vascular endothelium by antiphospholipid antibodies. J Clin Invest 1995, 96:2211-2219.
29. Xu C, Mao D, Holers V, et al.: A critical role for the murine complement regulator crry in fetomaternal tolerance. Science 2000, 287:498-501.
30. Kim YU, Kinoshita H, Molina H, et al.: Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both decay-accelerating factor and membrane cofactor protein. J Exp Med 1995, 181:151-159.
31. Holers M, Girardi G, Mo L, et al.: Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220.
32. Salmon JE, Girardi G, Holers VM: Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002, 61(Suppl II):ii46-ii50.
33. Salmon JE, Girardi G, Holers VM: Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus 2003, 12:535-538.
34. Girardi G, Berman J, Redecha P, et al.: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2001, 112:1644-1654.
35. Thurman J, Kraus D, Girardi G, et al.: A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 2005, 42:87-97.
36. Pierangeli S, Girardi G, Vega-Ostertag M, et al.: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005, 52:2120-2124. The experiments detailed in this study represent the most in-depth investigations of the mechanisms of thrombosis in the APS.
37. Pierangeli S, Vega-Ostertag M, Liu X, Girardi G: Complement activation: a novel mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci 2005, 1051:413-420. This paper summarizes the work done in animal models of APS.
38. Fischetti F, Durigutto P, Pellis V, et al.: Thrombus formation induced by antibodies to b2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346.
39. Laudes I, Chu J, Sikranth S, et al.: Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002, 160:1867-1875.
40. Ikeda K, Nagasawa K, Horiuchi T, et al.: C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997, 77:394-398.
41. Ritis K, Doumas M, Mastellos D, et al.: A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation cascades. J Immunol 2006, 177:4794-4802. The studies in this report tie together how complement activation can promote thrombophilia through induction of TF in neutrophils.
42. Wolberg A, Roubey R: Mechanisms of autoantibody- induced monocyte tissue factor expression. Thromb Res 2004, 114:391-396. The results of this study implicate monocytes in APS physiology through induction of TF.
43. Zhou H, Wolberg A, Roubey R: Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004, 104:2353-2358.
44. Pierangeli S, Vega-Ostertag M, Harris E: Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thromb Res 2004, 114:467-476. The effects of aPL on platelets and endothelial cells are nicely summarized in this report.
45. Khamashta M, Cuadrado M, Mujic F, et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993-997.
46. Rosove M, Brewer P: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303-308.
47. Ruiz-Irastorza G, Khamashta M, Hunt B, et al.: Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002, 162:1164-1169.
48. Crowther M, Ginsberg J, Julian J, et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-1138.
49. Finazzi G, Marchioli R, Brancaccio V, et al.: A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848-853.
50. Girardi G, Redecha P, Salmon J: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226. This important paper identifies complement inhibition as a crucial mechanism underlying the therapeutic efficacy of heparin in APS.